News and Press Releases
Gilbert To Officially Open New Development and GMP Manufacturing Facility
22 March 2024 -- Nottingham, UK -- UK-based contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions was joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor Professor Dame Sarah Gilbert, biotech industry representatives and...
Category: BioManufacturing, Clinical Trials, Manufacturing and Packing
Posted: March 22, 2024
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK, NG7 2TN
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
TMC Pharma champions holistic approach to medical services in rare disease drug development
13 March 2024 – In a recent webinar, rare disease specialist and global clinical research organisation (CRO) TMC Pharma gathered esteemed speakers to share insights into the scope of medical...
Category: Drug Discovery, Pharmaceutical
Posted: March 13, 2024
Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer
First time GMP manufacturing of a therapeutic IgE antibody has been achieved at scale GMP material to be used in phase 1b study in platinum-resistant ovarian cancer (PROC) patients scheduled...
Category: BioManufacturing
Posted: March 5, 2024
Clinigen launches ‘What is Possible?’ campaign to accelerate access to medicines on Rare Disease Day
With over 7,000 rare diseases that impact over 300 million people globally, just 5% of rare diseases have a licensed treatment 29 February 2024 -- London, UK -- Clinigen, the...
Category: Other
Posted: February 29, 2024
Kite Presents New Data for Yescarta (axicabtagene ciloleucel) CAR T-cell Therapy Highlighting Manufacturing Excellence and Cost-Effectiveness in the US
Data Highlights Industry-leading Manufacturing Success Rates for US Axicabtagene Ciloleucel Patients from Launch to Present Data Also Supports Cost-effectiveness of Axicabtagene Ciloleucel Versus Bispecific Antibodies 16 February 2024 – Stockley...
Category: BioManufacturing
Posted: February 21, 2024
Global End-to-End Solutions Partner to Life Sciences Organisations, AscellaHealth, joins Manchester Science Park
20 February 2024 -- Manchester, UK -- Global healthcare and specialty pharmacy solutions company providing innovative solutions to life sciences and biotech manufacturers, AscellaHealth, is expanding its UK presence with...
Category: Manufacturing and Packing
Posted: February 20, 2024
AscellaHealth, LLC 1055 Westlakes Drive Suite 175 Berwyn, PA 19312, US
Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...
Category: Biotechnology
Posted: February 7, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...
Category: Clinical Trials
Posted: October 24, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma · First Significant Improvement in Overall Survival in Two Decades...
Category: Pharmaceutical
Posted: October 23, 2023
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
Oral presentation highlights new findings about the efficacy of XACDURO for the treatment of monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus infections Researchers share global surveillance data on the in vitro activity of XERAVA (eravacycline) for injection on...
Category: Pharmaceutical
Posted: October 12, 2023
MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland
Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...
Category: Pharmaceutical
Posted: October 9, 2023
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
